Which of the following should NOT be considered when using testosterone in the dietary supplement? Visit www.urosource.com and answer the poll! Laparoscopic ureterocystoplasty before kidney transplantation Beyond prostate-specific antigen: alternate serum markers Combination of celecoxib with bacillus Calmette-Guerin immunotherapy against bladder cancer TVT-O versus TVT: a randomized trial in patients with different degrees of stress urinary incontinence Time for paradigm shift in treatment of hormone naive metastatic prostate cancer
Laparoscopic ureterocystoplasty before kidney transplantation Ramalingam et al. (2008) reported report of a case of total laparoscopic ureterocystoplasty in India. Laparoscopic ureterocystoplasty was performed to optimize the bladder function before kidney transplantation in a 23-year-old man. This patient had undergone bilateral cutaneous ureterostomy with fulguration of a posterior urethral valve at the age of 11 months. He underwent open surgical removal of multiple renal stones at age 10. He progressed to chronic renal failure at the age of 20, then hemodialysis was initiated. Because of grade IV vesicoureteral reflux and a poorly compliant bladder, the patient underwent laparoscopic ureterocystoplasty. Read more... Beyond prostate-specific antigen: alternate serum markers There is a need to improve existing methods for early diagnosis of prostate cancer and to identify men at risk for developing aggressive disease. In an effort to replace and/or supplement prostate-specific antigen (PSA) many serum analytes have been examined, but with little supportive data for clinical use. Recently, technological advances in molecular assays have improved investigational outcomes and have led to the discovery of a number of prospective markers with high specificity. Further promise for providing more accurate prostate cancer diagnosis and prognosis lies in proteomic array profiling and DNA methylation assays. In a review Ramirez et al. (2008) illustrated the current benefits and limitations of potentially useful prostate cancer serum markers that have considerable existing data and touches upon other future markers as well as the field of proteomics. Read more... Combination of celecoxib with bacillus Calmette-Guerin immunotherapy against bladder cancer Prostaglandin E2 (PGE2) is a potent immune modulator and known to suppress both tumour antigen-specific helper T (TH1) cells and the generation of cytotoxic T lymphocytes (CTLs). Dovedi et al. (2008) hypothesised that a combination of the cyclooxygenase 2 (COX-2) selective inhibitor celecoxib and intravesical bacillus Calmette-Guerin (BCG), an effective tumour immunoprophylaxis and ablative therapy for non-muscle-invasive bladder cancer, would be more effective than BCG alone. Read more... TVT-O versus TVT: a randomized trial in patients with different degrees of stress urinary incontinence Treating stress urinary incontinence (SUI) one can choose either tension-free vaginal procedure (TVT), a prolene tape placed anterior to the urethra through a minimal vaginal incision, or the transobturator vaginal tape inside-out (TVT-O). Araco et al. (2008) compared TVT-O and TVT in patients stratified according the severity of SUI. Read more... Time for paradigm shift in treatment of hormone naive metastatic prostate cancer The relative benefit of the chemotherapy administered in the neoadjuvant/adjuvant setting or simultaneously in advanced/metastatic stage of prostate cancer provided an impulse for further studies. Prof. Levent Turkeri from Istanbul used the European Urology Forum 2008 in Davos to consider a “time for paradigm shift in treatment of hormone naive metastatic prostate cancer“. Read more...
Copyright: © 2008 Urosource. All rights reserved To unsubscribe, send an e-mail to webmaster@urosource.com